Auto-titrating continuous positive airway pressure therapy in patients with chronic heart failure and obstructive sleep apnoea: a randomized placebo-controlled trial

Aims Obstructive sleep apnoea (OSA) is highly prevalent in patients with chronic heart failure (CHF) and may contribute to CHF progression. We aimed to determine whether treatment of OSA with continuous positive airway pressure (CPAP) would improve subjective and objective measures of heart failure...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2007-05, Vol.28 (10), p.1221-1227
Main Authors: Smith, Lindsay A., Vennelle, Marjorie, Gardner, Roy S., McDonagh, Theresa A., Denvir, Martin A., Douglas, Neil J., Newby, David E.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Chronic Disease
Continuous Positive Airway Pressure
Cross-Over Studies
Double-Blind Method
Electrocardiography
Exercise Test
Female
Heart Failure - complications
Humans
Male
Middle Aged
Prognosis
Quality of Life
Scotland
Sleep Apnea, Obstructive - complications
Sleep Apnea, Obstructive - therapy
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Obstructive sleep apnoea (OSA) is highly prevalent in patients with chronic heart failure (CHF) and may contribute to CHF progression. We aimed to determine whether treatment of OSA with continuous positive airway pressure (CPAP) would improve subjective and objective measures of heart failure severity in patients with CHF and OSA. Methods and results Twenty-six patients with stable symptomatic CHF and OSA were randomized to nocturnal auto-titrating CPAP or sham CPAP for 6 weeks each in crossover design. Study co-primary endpoints were changes in peak VO2 and 6 min walk distance. Secondary endpoints were changes in left ventricular ejection fraction, VE/VCO2 slope, plasma neurohormonal markers, and quality-of-life measures. Twenty-three patients completed the study protocol. Mean CPAP and sham CPAP usage were 3.5 ± 2.5 and 3.3 ± 2.2 h/night, respectively (P = 0.31). CPAP treatment was associated with improvements in daytime sleepiness (Epworth Sleepiness Score 7 ± 4 vs. 8 ± 5, P = 0.04) but not in other quality-of-life measures. There were no changes in other study endpoints. Conclusion In patients with CHF and OSA, auto-titrating CPAP improves daytime sleepiness but not other subjective or objective measures of CHF severity. These data suggest that the potential therapeutic benefits of CPAP in CHF are achieved by alleviation of OSA rather than by improvement in cardiac function.
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehm131